2024
Population Salutogenesis—The Future of Psychiatry?
van Os J, Guloksuz S. Population Salutogenesis—The Future of Psychiatry? JAMA Psychiatry 2024, 81: 115-116. PMID: 38117509, DOI: 10.1001/jamapsychiatry.2023.4582.Peer-Reviewed Original Research
2021
Impact of the first COVID-19 outbreak on mental health service utilisation at a Dutch mental health centre: retrospective observational study
Chow M, Noorthoorn E, Wierdsma A, van der Horst M, de Boer N, Guloksuz S, Luykx J. Impact of the first COVID-19 outbreak on mental health service utilisation at a Dutch mental health centre: retrospective observational study. BJPsych Open 2021, 7: e213. PMID: 34784994, PMCID: PMC8632375, DOI: 10.1192/bjo.2021.1049.Peer-Reviewed Original ResearchMental health service utilisationHealth service utilisationService utilisationFirst COVID-19 outbreakCare contactsPatient contactPsychotic disordersVideo consultationsCOVID-19 outbreakDiagnostic categoriesRetrospective observational studyMental healthcare deliveryMental health centersCOVID-19 pandemicDifferent diagnostic categoriesPre-pandemic periodRetrospective studyHealth centersObservational studyMental illnessPatientsHealthcare deliveryHealthcare institutesTelepsychiatryCOVID-19 lockdown
2019
The evidence‐based group‐level symptom‐reduction model as the organizing principle for mental health care: time for change?
van Os J, Guloksuz S, Vijn T, Hafkenscheid A, Delespaul P. The evidence‐based group‐level symptom‐reduction model as the organizing principle for mental health care: time for change? World Psychiatry 2019, 18: 88-96. PMID: 30600612, PMCID: PMC6313681, DOI: 10.1002/wps.20609.Peer-Reviewed Original ResearchMental health servicesMental health careHealth servicesSymptom reductionEvidence-based practice guidelinesMental vulnerabilityPublic mental health systemHealth careCommon mental disordersSelf-management toolsMental difficultiesMental health systemHigh prevalencePractice guidelinesEBP groupMental illnessMental disordersHealth systemCare interactionsSpecialist practitionersExistential domainDiagnosable disorderCarePeer supportTherapeutic relationship
2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight loss